Recombinetics’ regenerative medicine division, Regenevida, is redefining what’s possible in medicine. Regenevida’s mission is to create identical replicas of a patient’s own organ cells and tissues — with his or her own DNA — which has the potential to transform the face of modern medicine and drastically improve the quality-of-life for millions.
Cellular humanization of swine could provide unlimited supplies of therapeutic cells, tissues, and organs. Regenevida is pioneering individualized regenerative medicine by leveraging RCI’s visionary, gene-editing platform and expertise to develop swine as production systems, “oinkubators,” for cultivating patient blood cells, hepatocytes, tissues, and ultimately organs for human therapeutic applications.
While the programs to develop full human organs through these techniques requires further advances, Regenevida is already in position to use knowledge and practical expertise gained through its Surrogen swine models to cultivate patient blood cells, cardiomyocytes, hepatocytes and other tissues for human therapeutic applications.
Each of these steps along the path to organ development, present large-scale market opportunities with strong revenue potential. Strategic partnerships with leading hospitals and medical research firms are vital elements for Regenevida’s success. With its first-mover advantage, Recombinetics is already entering into collaborative R&D contracts.
Our leading-edge gene-editing technology is giving hope for millions of patients with heart and kidney diseases.
Read about our cardiomyocyte project with Mayo Clinic.
Watch the Freethink video on our company:
Learn about our multidisciplinary physician-scientist team in partnership with NYU Langone Medical Center:
To learn more about Regenevida, call 612-727-2000 or email email@example.com.